|ID:400 ||Lamotrigine||Search Links: General Info : Protocols : Patient Info|
|Description||The anticonvulsant lamotrigine is used in the treatment of a broad range of seizures and in conditions such as bipolar disorder.|
|Indication||Therapeutic drug monitoring (TDM), assessing non-compliance.|
|Additional Info||Lamotrigine is rapidly absorbed from the gastrointestinal tract and undergoes extensive metabolism. Steady state plasma concentrations are usually achieved at around five days however lamotrigine exhibits autoinduction within the first two weeks of commencing therapy which may prolong time to steady state. The metabolism of lamotrigine is affected by the use of concomitant enzyme inducers (e.g. carbamazepine, phenytoin) and inhibitors (e.g. sodium valproate) altering its half-life in adults from a mean of 24-35 hours to between a mean of approximately 14 and approximately 70 hours respectively.
Plasma concentrations appear to overlap between responders and non-responders and between those patients experiencing or not experiencing side effects. Toxicity occurs more frequently where plasma concentrations exceed 15 mg/L|
|Interpretation||Plasma clearance is dependent on interactions with other anticonvulsant drugs. There are large inter-individual differences between the dose/concentration response. Factors including age, pregnancy, disease states and concomitant medication will need to be considered when interpreting plasma concentrations.|
|Ref. Range (Male)||3.0 - 15.0|
|Ref. Range (Female)||3.0 - 15.0|
|Ref. Range (Paed)|| |
|Ref. Range Notes|| 3 to 15|
|IP Acute TAT||- Not Defined -|
|IP Routine TAT||- Not Defined -|
|GP Acute TAT||- Not Defined -|
|GP Routine TAT||- Not Defined -|
|Turnround Comment||Turnaround time stated by referral lab: 7 days|
Originally edited by : Eleanor McLaughlan. Last edited on 25/07/2020 12:47:32. Published By Eleanor McLaughaln on 25/07/2019 12:47:32.